Fatigue therapy in multiple sclerosis: Results of a double–blind, randomized, parallel trial of amantadine, pemoline, and placebo

Neurology

Volumn 45, Issue 11, 1995, Pages 1956-1961

  Krupp, Lauren B ^a   Coyle, P K ^a   Doscher, C ^b   Miller, A ^c   Cross, A H ^d   Jandorf, L ^b   Halper, J ^d   Johnson, B ^d   Morgante, L ^c   Grimson, R ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c Mai monides Medical Center and Hospital ^*  (United States)

^d Gimbel Multiple Sclerosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CENTRAL STIMULANT AGENT; PEMOLINE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AMANTADINE; ANALYSIS OF VARIANCE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEMOLINE;

EID: 0029400839     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.45.11.1956     Document Type: Article

References (31)

1. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984;65:135-138.
2. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988;45:435-437.
3. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
4. Schwartz J, Jandorf L, Krupp LB. The measurement of fatigue: a new scale. J Psychosom Res 1993;37:753-762.
5. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994;21:9-14.
6. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985;12:251-254.
7. Monks J. Experiencing symptoms in chronic illness: fatigue in multiple sclerosis. International Disability Studies 1989;11:78-83.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
9. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987;14:273-278.
10. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GPA. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42:1468-1471.
11. Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol 1988;45:1104-1106.
12. Abbott Laboratories Pharmaceutical Products Division. Cylert (pemoline) drug monograph. North Chicago, IL: Abbott Laboratories, 1975:7-9.
13. Pelman WE, Greenslade KE, Wodde-Hamilton M, et al. Relative efficacy of long acting stimulants on children with attention deficit hyperactivity disorder. A comparison of standard methylphenidate, sustained-release methylphenidate, sustained release dextroamphetamine, and pemoline. Pediatrics 1990;86:226-237.
14. Hayden FG, Douglas RG. Antiviral agents. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: John Wiley & Sons, 1990:375-377.
15. Schwab RS, Poskanzer DC, England AC, Young RR. Amantadine in Parkinson’s disease. Review of more than two years experience. JAMA 1972;222:792-795.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
17. Radloff LS. CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measures 1977;1:385-401.
18. Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurology 1993;43:2016-2018.
19. Krupp LB, LaRocca NC, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol 1990;17:1450-1452.
20. Krupp LB, Coyle PK, Sliwinski M. Fatigue in the elderly. In: Park M, Sage J, eds. Practical neurology of the elderly. New York: Marcel Dekker (in press).
21. Grossman M, Armstrong C, Onishi K, et al. Patterns of cognitive impairment in relapsing-remitting and chronic progressive multiple sclerosis. Neuropsychol Neuropsychiatr Behav Neurol 1994;7:194-210.
22. Brook RH, Ware HE, Davies-Avery D, et al. Overview of adult measures fielded in the Rand’s Health Insurance Study. Med Care 1979;17(suppl):l-55.
23. Ellis BW, Hohns MW, Lancaster R, et al. The St Mary’s Hospital Sleep Questionnaire: a study of reliability. Sleep 1981;4:94-97.
24. Valdini AF, Steinhardt S, Jaffe A. Demographic correlates of fatigue in a University Family Health Centre. Fam Pract 1987;4:103-104.
25. Hankin JR. The persistence of depressive symptomatology among prepaid group practice enrollees: an explanatory study. Am J Pub Health 1982;72:1000-1006.
26. Krupp LB, Jandorf L, Coyle PK, Mendelson WB. Sleep in chronic fatigue syndrome. J Psychosom Res 1993;37:325-331.
27. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-286.
28. Sandroni P, Walker C, Starr A. Fatigue in patients with multiple sclerosis. Arch Neurol 1992;49:517-524.
29. Leo GJ, Rao SM, St. Aubin-Faubert P, Glatt SL. Correlates of fatigue in multiple sclerosis. Ann Neurol 1987;22:152.
30. Cohen RA, Fisher J. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989;46:676-680.
31. Krupp LB, Sliwinski M, Masur DM, et al. Impact of fatigue treatment on cognitive functioning in MS. Ann Neurol 1993;34:248.